Purple Biotech (NASDAQ:PPBT – Get Free Report) had its target price hoisted by equities researchers at HC Wainwright from $8.00 to $33.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 388.89% from the stock’s current price.
Purple Biotech Trading Down 3.3 %
Shares of NASDAQ PPBT traded down $0.23 during trading on Friday, reaching $6.75. The stock had a trading volume of 10,682 shares, compared to its average volume of 11,035. The company has a market capitalization of $170.36 million, a price-to-earnings ratio of -8.33 and a beta of 1.07. Purple Biotech has a one year low of $6.05 and a one year high of $36.00.
Purple Biotech (NASDAQ:PPBT – Get Free Report) last issued its earnings results on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. As a group, equities analysts predict that Purple Biotech will post -0.32 earnings per share for the current year.
Institutional Inflows and Outflows
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.
Read More
- Five stocks we like better than Purple Biotech
- Stock Market Upgrades: What Are They?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to buy stock: A step-by-step guide for beginnersÂ
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- 3 REITs to Buy and Hold for the Long Term
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.